nach oben

Breast Cancer Research and Treatment

Erschienen in:

21.09.2018 | Review

Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis

verfasst von: Y. Shen, T. Fujii, N. T. Ueno, D. Tripathy, N. Fu, H. Zhou, J. Ning, L. Xiao

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Trastuzumab (H) with chemotherapy benefits patients with HER2+ breast cancer (BC); however, we lack head-to-head pairwise assessment of survival or cardiotoxicity for specific combinations. We sought to identify optimal combinations.

Methods

We searched PubMed, updated October 2017, using keywords “Breast Neoplasms/drug therapy,” “Trastuzumab,” and “Clinical Trial” and searched Cochrane Library. Our search included randomized trials of adjuvant H plus chemotherapy for early-stage HER2+ BC, and excluding trials of neoadjuvant therapy or without data to obtain hazard ratios (HRs) for outcomes. Following PRISMA guidelines, one investigator did initial search; two others independently confirmed and extracted information; and consensus with another investigator resolved disagreements. Before gathering data, we set outcomes of overall survival (OS), event-free survival (EFS), and severe cardiac adverse events (SCAEs). Analyzing 6 trials and 13,621 patients, we made direct and indirect comparisons using network meta-analysis on HR for OS or EFS and on odds ratio (OR) for SCAE; ranked therapy was done based on outcomes using p scores.

Results

Compared with anthracycline-cyclophosphamide with taxane (ACT), ACT with concurrent H (ACT+H) showed best OS (HR 0.63, 95% confidence interval [CI] 0.55, 0.72), followed by taxane and carboplatin (TC) with concurrent H (TC+H) (HR 0.77, 95% CI 0.59, 1) and ACT with sequential H (ACT-H) (HR 0.85, 95% CI 0.68, 1.05). Pairwise comparisons showed statistically significant OS benefit for ACT+H over others; similar results for EFS. TC+H showed statistically significant lower SCAE risk compared to ACT+H (OR 0.13, 95% CI 0.03, 0.61).

Conclusions

Concurrent H with ACT or TC showed most clinical benefit for early-stage HER2+ BC; TC+H had lowest cardiotoxicity.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Jemal A. Cancer statistics (2016) CA Cancer J Clin 2016; 66(1):7–30CrossRef

Hynes N, Stern DF (1994) The biology of ErbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198(2–3):165–184PubMed

Yarden Y, Sliwkowsk MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127–137CrossRef

Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 235(4785):177–182CrossRef

Slamon DJ, Goldophin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712CrossRef

Arboleda MJ, Lyons JF, Kabbinavar FF et al (2003) Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63(1):196–206PubMed

Benz CC, Scott GK, Sarup JC et al (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24(2):85–95CrossRef

De Luca A, Carotenuto A, Rachiglio A et al (2008) The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214(3):559–567CrossRef

Feigin ME, Muthuswamy SK (2009) ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion. Exp Cell Res 315(4):707–716CrossRef

10.

Izumi Y, Xu L, di Tomaso E et al (2002) Tumour biology: herceptin acts as an antiangiogenic cocktail. Nature 416(6878):279–280CrossRef

11.

Marcotte R, Muller WJ (2008) Signal transduction in transgenic mouse models of human breast cancer—implications for human breast cancer. J Mammary Gland Biol Neoplasia 13(3):323–335CrossRef

12.

Pietras RJ, Arboleda J, Reese DM et al (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10(12):2435–2446PubMed

13.

She QB, Chandarlapaty S, Ye Q et al (2008) Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 3(8):e3065CrossRef

14.

Baselga J, Carbonell X, Castañeda-Soto NJ et al (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23(10):162–171CrossRef

15.

Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792CrossRef

16.

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (2015) https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 5 Aug 2015

17.

De Laurentiis M, Cancello G, D’Agostino D et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26(1):44–53CrossRef

18.

Gandhi S, Fletcher GG, Eisen A et al (2015) Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol 22(Suppl 1):S82–S94PubMedPubMedCentral

19.

Tan-Chiu E, Yothers G, Romond E et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23(31):7811–7819CrossRef

20.

Perez EA, Romond EH, Suman VJ et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33):3744–3752CrossRef

21.

Romond EH, Jeong JH, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30(31):3792–3799CrossRef

22.

Perez EA, Suman VJ, Davidson NE et al (2011) Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 29(34):4491–4497CrossRef

23.

Genentech. Herceptin (trastuzumab) development timeline. Genentech product information. https://www.gene.com/media/product-information/herceptin-development-timeline. Accessed 20 Oct 2017

24.

Peto R, Davies C, Godwin J et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444CrossRef

25.

Blum JL, Flynn PJ, Yothers G et al (2017) Anthracyclines in early breast cancer: the ABC Trials—USOR 06–090, NSABP B-46-I/USOR 07132, NSABP B-49 (NRG Oncology). J Clin Oncol 35:2647–2655CrossRef

26.

Bafeta A, Trinquart L, Seror R, Ravaud P (2014) Reporting of results from network meta-analyses: methodological systematic review. BMJ 348:g1741CrossRef

27.

Neupane B, Richer D, Bonner AJ et al (2014) Network meta-analysis using R: a review of currently available automated packages. PLoS ONE 9(12):e115065CrossRef

28.

Zhang J, Carlin BP, Neaton JD et al (2014) Network meta-analysis of randomized clinical trials: reporting the proper summaries. Clin Trials 11(2):246–262CrossRef

29.

Tonin FS, Rotta I, Mendes AM, Pontarolo R (2017) Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada) 15(1):943CrossRef

30.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):31–34CrossRef

31.

Joensuu H, Bono P, Kataja V et al (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 27(34):5685–5692CrossRef

32.

Spielmann M, Roché H, Delozier T et al (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27(36):6129–6134CrossRef

33.

Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in Her2-positive breast cancer. N Engl J Med 365(14):1273–1283CrossRef

34.

Cameron D, Piccart-Gebhart MJ, Gelber RD et al (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389(10075):1195–1205CrossRef

35.

Goldstein LJ, O’Neill A, Sparano JA et al (2008) Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 26(25):4092–4099CrossRef

36.

Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22):2302–2313CrossRef

37.

Martín M, Seguí MA, Antón A et al (2010) Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363(23):2200–2210CrossRef

38.

Higgins J, Green S. (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. the cochrane collaboration. https://www.cochrane-handbook.org.

39.

Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med 17(24):2815–2834. Erratum in Stat Med 2004; 23(11): 1817CrossRef

40.

Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16CrossRef

41.

Rücker G (2012) Network meta-analysis, electrical networks and graph theory. Res Synth Methods 3(4):312–324CrossRef

42.

Rücker G, Schwarzer G (2015) Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 15:58CrossRef

43.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560CrossRef

44.

Krahn U, Binder H, König J (2013) A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol 13:35CrossRef

45.

Jackson D, White IR, Riley RD (2012) Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 31(29):3805–3820CrossRef

46.

Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021–1028CrossRef

47.

Clinical Trials.gov. Trial Identifier: NCT00021255. Cancer International Research Group. https://clinicaltrials.gov/ct2/show/NCT00021255. Accessed 30 Nov 2017

48.

Dahabreh IJ, Linardou H, Siannis F et al (2008) Trastuzumab in the adjuvant treatment of early stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13(6):620–630CrossRef

49.

Viani GA, Afonso SL, Stefano EJ et al (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153CrossRef

50.

Nagayama A, Hayashida T, Jinno H et al (2014) Comparative effectiveness of neoadjuvant therapy for HER2–positive breast cancer: a network meta-analysis. J Natl Cancer Inst 106(9):pii:dju203CrossRef

51.

Chavez-MacGregor M, Zhang N, Buchholz TA et al (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31(33):4222–4228CrossRef

52.

Eiermann W, Pienkowski T, Crown J et al (2011) Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 29(29):3877–3884CrossRef

53.

Gradishar WG, Anderson BO, Blair SL et al (2014) Breast cancer version 3.2014. J Natl Compr Cancer Netw 12(4):542–590CrossRef

54.

Ganz PA, Land SR, Geyer CE et al (2009) NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. Cancer Res 69(2 Suppl):Abst 76

55.

Baselga J, Cortés J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119CrossRef

56.

Minckwitz G, Procter MJ et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377:122–131CrossRef

57.

Moreno-Aspitia A, Holmes EM et al (2017) Updated results from the phase III ALTTO trial (BIG 2–06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L + T) in the adjuvant treatment of HER2-positive early breast cancer. J Clin Oncol 35:15_suppl, 502–502CrossRef

Titel: Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis
verfasst von: Y. Shen
T. Fujii
N. T. Ueno
D. Tripathy
N. Fu
H. Zhou
J. Ning
L. Xiao
Publikationsdatum: 21.09.2018
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4969-6

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Dietary intervention among breast cancer survivors increased adherence to a Mediterranean-style, anti-inflammatory dietary pattern: the Rx for Better Breast Health Randomized Controlled Trial

A synonymous germline variant PALB2 c.18G>T (p.Gly6=) disrupts normal splicing in a family with pancreatic and breast cancers

T-Type voltage gated calcium channels: a target in breast cancer?

COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer

Correction to: Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer

Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer?

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie